Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Please provide your email address to receive an email when new articles are posted on . Remicade trough levels 2 weeks after infusion were significantly lower in patients with acute severe ulcerative ...

If you have a certain type of arthritis or disease that causes inflammation, your doctor may recommend Remicade. It’s a prescription drug used in certain situations to treat: Remicade contains the ...

Remicade (infliximab) is a prescription drug that’s used to treat certain autoimmune conditions, such as rheumatoid arthritis. Remicade can cause side effects that range from mild to serious. Examples ...

LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year ...

In a double-blind multicenter study by Targan et al., [50] 108 patients with active, refractory, moderate to severe CD (a mean CDAI score at baseline of approximately 300 despite treatment with ...

July 11, 2002 -- The U.S. Food and Drug Administration (FDA) has granted marketing approval to infliximab (Remicade) to provide long-term remission-level control of moderate to severe Crohn's disease.

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...